Healthspan Capital
hybrid fundWebsite
Fund rating
0.0 / 35
0 published reviews
No per-dimension scores yet.
Published reviews
About
Direct fit as an early-stage longevity VC investing in biotechnology startups developing therapies to slow or reverse aging, which aligns with OpenDrugs' longevity, biotech, and AI-enabled research platform focus.